Gabrail Cancer Center

Clinical research site in Canton, Ohio

Part of Gabrail Cancer Center

As of July 2026, 19 paid clinical trials are recruiting at Gabrail Cancer Center in Canton, Ohio. Active studies at this site cover conditions such as Colorectal Neoplasms, Hematologic Malignancies and Myelofibrosis. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Gabrail Cancer Center (19)

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

for Breast Neoplasms

116 locations incl. Anchorage

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07174336·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

for Colorectal Neoplasms

68 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06750094·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

for Colorectal Neoplasms

79 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06662786·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

for Leukemia, Myeloid, Acute

51 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06852222·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

for Plasma Cell Myeloma Refractory

34 locations incl. Phoenix

Sponsor: Sanofi

Sex: All·Age: 18+

Code: NCT06356571·Phase 2·Recruiting·Listed Apr 2024

Apply to this trial

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

58 locations incl. Birmingham

Sponsor: Kartos Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06479135·Phase 3·Recruiting·Listed Jun 2024

Apply to this trial

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

11 locations incl. Springdale

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07518186·Phase 3·Recruiting·Listed Apr 2026

Apply to this trial

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

for Ras-mutated Metastatic Colorectal Cancer

13 locations incl. Homewood

Sponsor: Oncolytics Biotech

Sex: All·Age: 18+

Code: NCT07446322·Phase 2·Recruiting·Listed Mar 2026

Apply to this trial

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

for Solid Malignancies

17 locations incl. Duarte

Sponsor: Immunome, Inc.

Sex: All·Age: 18+

Code: NCT06823167·Phase 1·Recruiting·Listed Feb 2025

Apply to this trial

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

19 locations incl. Anchorage

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06899126·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

for Breast Cancer, Metastatic

21 locations incl. Tucson

Sponsor: ALX Oncology Inc.

Sex: All·Age: 18+

Code: NCT07007559·Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

for Carcinoma, Non-Small-Cell Lung

12 locations incl. Anchorage

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06855771·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

for Higher-risk Myelodysplastic Syndromes

14 locations incl. Los Angeles

Sponsor: Akeso

Sex: All·Age: 18+

Code: NCT06196203·Phase 2·Recruiting·Listed Jan 2024

Apply to this trial

Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

for Advanced Solid Tumors

3 locations incl. Chicago

Sponsor: Acrotech Biopharma Inc.

Sex: All·Age: 18+

Code: NCT07036133·Phase 1·Recruiting·Listed Jun 2025

Apply to this trial

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

for Acute Myeloid Leukemia (AML)

7 locations incl. Denver

Sponsor: Aptevo Therapeutics

Sex: All·Age: 18+

Code: NCT06634394·Phase 1·Recruiting·Listed Oct 2024

Apply to this trial

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

for Solid Tumor

2 locations incl. Canton

Sponsor: Lamassu Bio Inc

Sex: All·Age: 18+

Code: NCT06578624·Phase 1, Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

for CLL/SLL

7 locations incl. Duarte

Sponsor: Ascentage Pharma Group Inc.

Sex: All·Age: 18 - 85

Code: NCT04215809·Phase 1·Recruiting·Listed Jan 2020

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

for Triple Negative Breast Cancer

3 locations incl. Columbus

Sponsor: Jina Pharmaceuticals Inc.

Sex: Female·Age: 18 - 65

Code: NCT03671044·Phase 3·Recruiting·Listed Sep 2018

Apply to this trial

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

4 locations incl. Birmingham

Sponsor: Telios Pharma, Inc.

Sex: All·Age: 18+

Code: NCT05280509·Phase 1, Phase 2·Recruiting·Listed Mar 2022

Apply to this trial

More research sites in Canton

Aultman Health Foundation (31 trials)
Gabrail Cancer Center Research (15 trials)
Aultman Hospital (9 trials)
Cleveland Clinic Mercy Hospital (9 trials)
GSK Investigational Site (6 trials)
Gabrail Cancer & Research Center (5 trials)
Apex Clinical Research Center, LLC (4 trials)
Gabrail Cancer Research Center (3 trials)
Apex Clinical Research Center - Canton (2 trials)
Diabetes and Endocrinology Associates of Stark County (2 trials)

Explore more

Paid clinical trials in Canton, OH · Ohio clinical trials